β-
thalassemia is a genetic
hemoglobin (Hb) disorder that affects millions of people world-wide. It is characterized by ineffective erythropoiesis and
anemia. The resultant chronic
anemia can require life-long
blood transfusion regimens, leading to secondary
hemochromatosis. Moreover, the abnormal red blood cells (RBCs) from β-
thalassemia patients are prone to hemolytic events that release cell-free Hb and
heme causing a series of events that result in oxidative organ and tissue damage. In this study, β-thalassemic mice were treated with a
protein scavenger for six weeks,
apohemoglobin-
haptoglobin (apoHb-Hp), this
protein scavenges cell free Hb and
heme. We hypothesize that scavenging cell-free Hb and
heme will lead to a positive therapeutic event. After the apoHb-hp treatment it was observed to reduce the weight of the liver and spleen and show an improvement in liver function by a drop in ALT, AST, and ALP markers. ApoHb-hp treatment also hints at an improved RBC half-life as the number of reticulocytes decreased, the mean corpuscular volume (MCV) increased, mean corpuscular hemoglobin increase and the RBC distribution width decreased. Furthermore, apoHb-Hp treatment reduced circulating serum
iron concentration and
transferrin saturation concentration. Based on these outcomes, introducing a scavenger
protein can benefit β-thalassemic mice. This study demonstrated that apoHb-Hp treatment may be a viable strategy to mitigate toxicities associated with cell free Hb and
heme, a driver of β-thalassemic issues.